Lacosamide interactions

Food & lifestyle

• alcohol

  Moderate

  Synergy

  Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents. Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.

  What to do: Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

  5 sources

  1. Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc. (1990):
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  4. "Product Information. Fycompa (perampanel)." Eisai Inc (2012):
  5. "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc (2015):

Conditions

Conditions in which Lacosamide needs care, as documented in this source.

• Depressive Disorder

  Major

  Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication. Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior. Caregivers and family should be alert for the emergence or worsening of symptoms. Behaviors of concern should be reported immediately to the healthcare providers.

  9 sources

  1. "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals (2002):
  2. "Product Information. Depakene (valproic acid)." Abbott Pharmaceutical (2001):
  3. "Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical (2001):
  4. "Product Information. Lamictal (lamotrigine)." Glaxo Wellcome (2001):
  5. "Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical (2001):
  6. "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals (2001):
  7. "Product Information. Vimpat (lacosamide)." UCB Pharma Inc (2008):
  8. "Product Information. Banzel (rufinamide)." Eisai Inc (2008):

  Show all 9 sourcesShow fewer sources

  9. "Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc (2013):

• Cardiovascular Diseases

  Moderate

  Dose dependent prolongation in PR interval has been observed with the use of lacosamide. This drug should be used with caution in patients with known conduction abnormalities (AV block, sick sinus syndrome) in patients with sodium channelopathies (e.g., Brugada syndrome), with severe cardiac disease (myocardial ischemia, heart failure, structural disease), or in treatment with other drugs that also prolong PR interval. An ECG is recommended before beginning treatment, and after dose titration to a steady maintenance dose.

  1 source

  1. "Product Information. Vimpat (lacosamide)." UCB Pharma Inc (2008):

• Hepatic Insufficiency

  Moderate

  Patients with mild to moderate hepatic impairment should be observed closely during lacosamide dose titration. A maximum dose of 300 mg/day is recommended for these patients. Lacosamide has not been evaluated in patients with severe hepatic impairment, so its use is not recommended in this group of patients.

  1 source

  1. "Product Information. Vimpat (lacosamide)." UCB Pharma Inc (2008):

• Kidney Diseases

  Moderate

  A maximum dose of 300 mg/day of lacosamide is recommended for patients with severe renal impairment (CrCl <30 mL/min) and in patients with end stage renal disease. Lacosamide is effectively removed from plasma by hemodialysis and a dose supplementation of 50% should be considered following this procedure. Dose titration should be done with caution in all renally impaired patients.

  1 source

  1. "Product Information. Vimpat (lacosamide)." UCB Pharma Inc (2008):